Nalaganje...
Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway
AIM: Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer. However, only part of patients benefit from regorafenib, and the mechanisms of regorafenib’s anti-tumor effect need furthe...
Shranjeno v:
| izdano v: | PLoS One |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Public Library of Science
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5425213/ https://ncbi.nlm.nih.gov/pubmed/28489887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177335 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|